Medigen Vaccine Biologics (6547) - Cash Flow Conversion Efficiency

Latest as of June 2026: -0.026x

Based on the latest financial reports, Medigen Vaccine Biologics (6547) has a cash flow conversion efficiency ratio of -0.026x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-91.20 Million ≈ $-2.87 Million USD) by net assets (NT$3.56 Billion ≈ $112.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Medigen Vaccine Biologics for the company's overall valuation and market capitalisation.

Medigen Vaccine Biologics - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Medigen Vaccine Biologics's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Medigen Vaccine Biologics Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Medigen Vaccine Biologics ranked by their cash flow conversion efficiency. Explore Medigen Vaccine Biologics cash earnings quality to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Enovix Corp NASDAQ:ENVX	-0.086x
Zhongbai Holdings Group Co Ltd SHE:000759	-0.009x
SNP Schneider-Neureither & Partner SE XETRA:SHF	0.083x
GurSel Turizm Tasimacilik Ve Servis Ticaret AS IS:GRSEL	0.159x
Envela Corp NYSE MKT:ELA	0.279x
Luyan Pharma Co Ltd SHE:002788	0.035x
Haoxiangni Jujube Co Ltd SHE:002582	0.029x
Ciputra Development Tbk JK:CTRA	0.004x

Annual Cash Flow Conversion Efficiency for Medigen Vaccine Biologics (2012–2025)

The table below shows the annual cash flow conversion efficiency of Medigen Vaccine Biologics from 2012 to 2025. View Medigen Vaccine Biologics (6547) stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	NT$3.48 Billion ≈ $109.62 Million	NT$-49.09 Million ≈ $-1.55 Million	-0.014x	-233.28%
2024-12-31	NT$3.85 Billion ≈ $121.30 Million	NT$40.75 Million ≈ $1.28 Million	0.011x	+108.52%
2023-12-31	NT$3.85 Billion ≈ $121.19 Million	NT$-477.75 Million ≈ $-15.05 Million	-0.124x	+43.27%
2022-12-31	NT$5.03 Billion ≈ $158.44 Million	NT$-1.10 Billion ≈ $-34.69 Million	-0.219x	-276.53%
2021-12-31	NT$4.68 Billion ≈ $147.32 Million	NT$579.89 Million ≈ $18.27 Million	0.124x	+166.03%
2020-12-31	NT$3.14 Billion ≈ $98.97 Million	NT$-589.97 Million ≈ $-18.59 Million	-0.188x	+44.52%
2019-12-31	NT$1.37 Billion ≈ $43.06 Million	NT$-462.65 Million ≈ $-14.58 Million	-0.338x	-53.14%
2018-12-31	NT$1.61 Billion ≈ $50.79 Million	NT$-356.33 Million ≈ $-11.23 Million	-0.221x	-54.92%
2017-12-31	NT$1.52 Billion ≈ $47.92 Million	NT$-217.03 Million ≈ $-6.84 Million	-0.143x	-28.34%
2016-12-31	NT$1.47 Billion ≈ $46.30 Million	NT$-163.37 Million ≈ $-5.15 Million	-0.111x	-169.10%
2015-12-31	NT$1.34 Billion ≈ $42.35 Million	NT$216.26 Million ≈ $6.81 Million	0.161x	+133.76%
2014-12-31	NT$1.08 Billion ≈ $33.99 Million	NT$-513.98 Million ≈ $-16.19 Million	-0.476x	-201.54%
2013-12-31	NT$457.94 Million ≈ $14.43 Million	NT$-72.36 Million ≈ $-2.28 Million	-0.158x	-269.62%
2012-12-31	NT$128.00 Million ≈ $4.03 Million	NT$-5.47 Million ≈ $-172.40K	-0.043x	--

About Medigen Vaccine Biologics

TWO:6547 Taiwan Biotechnology

Market Cap

$619.37 Million

NT$19.66 Billion TWD

Market Cap Rank

#11235 Global

#401 in Taiwan

Share Price

NT$59.80

Change (1 day)

-1.64%

52-Week Range

NT$33.75 - NT$68.10

All Time High

NT$280.20